All Blogs
Sep 29, 2022
Asahi Intecc Partners with Penumbra; Prosoma and EVERSANA Announce Commercialisation Partnership; Zynex Starts Enrollment in the Blood Loss Detection Clinical Trial; Reva Initiates Enrollment in the MOTIV IDE Clinical Trial; FDA Clearance to QT Imaging to Calculate Fibroglandular Volume of the Breast; FDA 510k Clearance to iMediSync’s EEG scanner ‘iSyncWave’
Asahi Intecc partners with Penumbra to roll out Indigo System in Japan On September 22, 2022, Asahi Intecc, a Surgical and medical instrument manufacturing company, partnered with Penumbra, a medical device company headquartered in Alameda, California, to roll out Indigo System in Japan. After getting regulat...
Read More...
Sep 28, 2022
Evaluating the Growing Role of Devices in the Rehabilitation of Hearing Impairment
Hearing loss is a growing public health concern, and the number of cases is rising globally at a significant pace. As per the WHO, more than 1.5 billion people (nearly 20% of the global population) live with hearing loss, and 430 million of them have disabling hearing loss. According to the NIDCD, in the United Sta...
Read More...
Sep 27, 2022
Daiichi Sankyo’s Ezharmia; Pfizer & Sangamo Hemophilia A Gene Therapy Trial; Approval for Fennec’s Pedmark; FDA Approves UBE and Santen’s OMLONTI; EC Approves AstraZeneca’s Tezspire; FDA Approves Selpercatinib; FDA Grants Accelerated Approval to Eli Lilly’s Retevmo; GSK & Spero Announce Exclusive License Agreement
Daiichi Sankyo Receives the First Approval for its Blood Cancer Drug Ezharmia Daiichi Sankyo has received the first global approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL). The Japanese Ministry of ...
Read More...
Sep 26, 2022
PDE4-B Inhibitors: A Promising Target for Idiopathic Pulmonary Fibrosis Treatment
Idiopathic pulmonary fibrosis (IPF) is a rare, sporadic, and fatal interstitial lung disease. As the morbidity and mortality rates associated with IPF remain high, prompt idiopathic pulmonary fibrosis treatment is critical to safeguard individuals’ lung function, reduce the risk of acute exacerbations, and improve ...
Read More...
Jul 14, 2025
How Novel Therapies Could Transform the Ulcerative Colitis Treatment Landscape
Almost two decades ago, there were limited options for ulcerative colitis treatment. Choosing the right ulcerative colitis drugs depends on the severity of the condition and the patient's response to previous therapies. To manage patients effectively, physicians often prescribe a combination of ulcerative colitis m...
Read More...
Sep 22, 2022
Smith+Nephew’s OR3O Dual Mobility System; Medtronic Launches the Evolut FX Next-Gen TAVR System; FDA Approves Edwards’s Pascal Precision Transcatheter Valve Repair System; FDA Clearance to Zimmer Biomet’s Identity Shoulder System; Otsuka Announces Results of RADIANCE II Trial; Smith+Nephew Announces Data for its REGENETEN™ Bioinductive Implant
OR3O™ Dual Mobility System launched by Smith+Nephew in Japan for use in primary and revision hip arthroplasty On September 20, 2022, Smith+Nephew, a leading global portfolio medical technology business, announced the launch of OR3O Dual Mobility System for use in primary and revision hip arthro...
Read More...
Sep 21, 2022
What Compelling Applications is Brain-computer Interfacing Bringing to the Healthcare Market?
Technological advancement is bringing in a new frontier in the healthcare segment with innovative tools and resourceful applications. With each passing day, it unlocks new mysteries and scales greater heights toward solving several underlying challenges. Now moving forward, how fascinating it will be if someone tel...
Read More...
Sep 20, 2022
AstraZeneca’s Danicopan Trial; CHMP Recommends Sanofi/AstraZeneca’s nirsevimab; Akero’s NASH Drug Trial; FDA Grants Orphan Drug Status to SY-5609; BMS’s Opdivo Trial Results; Pfizer to File for FDA Approval for Meningitis Vaccine; EMA Orphan Drug Designation to CAN-2409; FDA Starts Priority Review of Chiesi ‘s velmanase alfa
AstraZeneca’s Danicopan Shows Positive Results in Phase III Trial Danicopan, an oral Factor D inhibitor developed by AstraZeneca, was expected to fail a phase II trial in rare kidney disease in 2020, but a new readout could revive the drug. Danicopan (ALXN2040) has demonstrated efficacy as an adjunct treatment f...
Read More...
Sep 19, 2022
Adial’s Micro-formulation: Opening New Massive Alcohol Use Disorder Treatment Market Opportunities
Key Highlights Through the use of genetic screening, i.e., a companion genetic bio-marker intended to identify patients most likely to respond to therapy, AD04 humanizes the alcohol use disorder treatment, which could lead to an increase in the usage of AD04Without the need for abstinence, AD04’s novel mechanism...
Read More...
Sep 16, 2022
Focal Segmental Glomerulosclerosis Market: Unfolding Insights into the Future
Currently, there are no FDA-approved therapies for FSGS. However, the therapeutic focal segmental glomerulosclerosis market in the seven major geographies mainly comprises off-label focal segmental glomerulosclerosis treatment options. The off-label therapies majorly include nonimmune therapies in conjunction wi...
Read More...